**AUB KQ1 Evidence Table (Reference ID #1184)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality**  **Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**  Cameron et al., 1987  **Country:**  United Kingdom  **Enrollment** **period:**  NR  **Intervention** **setting:**  Hospital  **Funding:**  Birthright research grant, Royal College of Obstetricians and Gynaecologists  **Author industry relationship disclosures:**  NR  **Study Design:**  RCT  **Blinding:**  NR | **Intervention:**  Mefenamic acid 500 mg three times per day for the first five days of cycle;  **Comparator:**  Norethisterone 5 mg two times per day on cycle days 15 to 25;  Progesterone-impregnated coil releasing 65 mcg progesterone  daily  Two control cycles, two treatment cycles  **Groupsa:**  **G1:** Mefenamic acid  **G2:** Norethisterone  **G3:** Progesterone-impregnated coil  **Followup:**  4 months | **Inclusion criteria:**  Mean MBL >50 ml  **Exclusion criteria:**  See inclusion criteria  **N at enrollment:**  **G1:** 8  **G2:** 8  **G3:** 8  **N at followup:**  **G1:** 6  **G2:** 7  **G3:** 6  **Age, median years (range):**  **G1:** 40 (33, 48)  **G2:** 39 (35, 46)  **G3:** 40 (29, 42)  **BMI:**  NR  **Weight, median kg (range):**  **G1:** 64 (50, 70)  **G2:** 64 (52, 73)  **G3:** 70 (54, 89)  **Height, median cm (range):**  **G1:** 162 (149, 164)  **G2:** 164 (152, 169)  **G3:** 162 (145, 164)  **Parity, median (range):**  **G1:** 4 (2, 4)  **G2:** 4 (1, 4)  **G3:** 2 (2, 4)  **Race/ethnicity:**  NR | **Bleeding:**  MBL measured by alkaline hematin method, median ml (range):  **G1:** 68 (61, 169)  **G2:** 94 (55, 312)  **G3:** 71 (56, 164)  MBL measured by alkaline hematin method, followup group, median ml (range):  **G1:** 85 (68, 169)  **G2:** 131 (55, 259)  **G3:** 64 (56, 164)  Number of bleeding days, median (range):  **G1:** 5 (4, 7)  **G2:** 6 (4, 7)  **G3:** 5 (4, 6)  Cycle length, median days (range):  **G1:** 28 (23, 38)  **G2:** 28 (24, 30)  **G3:** 26 (23, 30)  Endometrial prostaglandin, median pg/mg (range):  **G1:** 412 (256, 9506)  **G2:** 770 (152, 2251)  **G3:** 842 (265, 1630) | **Bleeding:**  MBL measured by alkaline hematin method, median ml (range):  **G1:** 47 (39, 210)  **G2:** 110 (24, 222)  **G3:** 45 (31, 77)  **G1 vs. BL:** p=0.05  **G2 vs. BL:** p=NS  **G3 vs. BL:** p<0.05  Number of bleeding days:  No difference vs. baselineb  Endometrial prostaglandin, median pg/mg (range):  **G1:** 546 (412, 3434)  **G2:** 985 (55, 1987)  **G3:** 273 (178, 832)  **G1 vs. BL:** p=NS  **G2 vs. BL:** p=NS  **G3 vs. BL:** p=0.05  **Quality of life:**  NR  **Pain:**  NR  **Sexual function:**  NR  **Patient satisfaction:**  NR  **Fertility:**  NR  **Time to conception:**  NR  **Additional interventions:**  NR  **Adverse events:**  NR | **Overall quality:**  Poor  **Risk of bias:**  Randomization:  Unclear  Allocation concealment:  Unclear  Selective reporting:  Unclear  Blinding patients/personnel:  High  Blinding outcome assessment:  High  Incomplete outcome reporting:  Unclear  Other:  Unclear |

**Table Notes**: a Does not include a treatment group randomized to danazol (n=6); b Baseline refers to control cycles.